Loading organizations...
§ Private Profile · Cambridge, MA, USA
Biotechnology company developing cell-penetrating miniproteins to access hard-to-reach targets for cancer and life-threatening diseases.
FogPharma has raised $506.0M across 4 funding rounds.
Key people at FogPharma.
FogPharma has raised $506.0M in total across 4 funding rounds.
Based in Cambridge, Massachusetts, FogPharma is a biotechnology company that develops cell-penetrating miniproteins designed to target hard-to-reach intracellular drivers of cancer and other severe diseases. The enterprise utilizes a high-throughput drug discovery platform to create these spiral-shaped therapeutics, operating out of a custom 120,000-square-foot research and development facility. To advance its first oncology treatment toward human clinical trials, the organization has secured significant capital, including a $178 million Series D financing round in 2022. This recent funding followed earlier venture rounds, including a $66 million Series B and an initial $11 million seed investment. The financial backing comes from a global syndicate of prominent institutional and private investors, featuring GV, Horizons Ventures, Deerfield Management, 6 Dimensions Capital, and Jack Ma. FogPharma was originally founded in 2015 by Gregory Verdine, Sir David Lane, and Weiqing Zhou.
Parabilis Medicines (formerly FogPharma) is a clinical-stage biopharmaceutical company pioneering Helicon™ therapeutics, a novel class of stabilized helical peptide drugs designed to target previously undruggable proteins, primarily for cancer treatment.[1][2][3][6] It serves patients with solid tumors like colorectal cancer (CRC) by addressing limitations of conventional precision medicines through its AI- and physics-integrated discovery platform, which accelerates drug development against intractable targets such as the β-catenin:TCF interaction.[1][3][8] The company's lead candidate, FOG-001, is in Phase 1/2 trials as the first direct inhibitor of this pathway, with additional programs in protein degraders and radioligand therapies; it has raised over $145 million in recent financing, signaling strong growth momentum amid a booming radiopharma sector.[3][4][5][8]
Founded in 2016 (with some sources noting 2015) by Greg Verdine, Ph.D., a pioneer in drugging undruggable targets, FogPharma emerged from Verdine's vision to create cell-penetrating miniproteins (CPMPs) and Helicons—short, helix-shaped amino acid chains that overcome barriers of traditional small-molecule and biologic drugs.[1][2][7][8] Early traction came from assembling a powerhouse team, including experts in cancer biology and AI, backed by a syndicate of top investors; pivotal moments include becoming a Fierce 15 winner in 2023, a $145 million financing in 2024, and a $178 million Series D.[5][8] In 2025, the company rebranded to Parabilis Medicines to reflect its expanded ambitions in AI-driven discovery and global patient reach, while advancing FOG-001 into clinical enrollment for CRC and other solid tumors just 16 months post-discovery.[3][6][8][9]
Parabilis rides the radiopharma and precision oncology boom, where demand for tumor-targeted radiation therapies is surging due to successes like Novartis' Pluvicto, drawing billions in VC and Big Pharma acquisitions.[4] Timing is ideal amid AI's rise in biotech, enabling faster targeting of undruggable proteins—a market force favoring platforms like Helicons over legacy small molecules, especially for solid tumors resistant to immunotherapy.[1][3][4] By influencing the ecosystem through collaborations (e.g., Artbio for Pb-212 radiopharma) and redefining "druggability," Parabilis expands the therapeutic universe, potentially reshaping cancer treatment paradigms and inspiring hybrid peptide-radioligand innovations.[4][6]
Parabilis is poised to advance FOG-001 toward pivotal data in CRC/solid tumors, expand its four late-stage discovery programs, and deepen AI enhancements for degraders and radiopharmas, leveraging its $145M+ war chest.[3][4][5] Trends like AI-biophysics fusion and short half-life isotopes (e.g., Pb-212 for precise imaging) will propel growth, with potential Big Pharma partnerships amplifying influence amid oncology M&A fervor.[4][8] As it evolves from FogPharma's helix vision to a global patient-focused powerhouse, Parabilis exemplifies how targeted innovation achieves universal druggability, delivering years to life for intractable cancers.[2][9]
FogPharma has raised $506.0M in total across 4 funding rounds.
FogPharma's investors include Thilo Schroeder, Lux Capital, Nextech Invest, The Column Group, venBio, Alex Gorsky, ARCH Venture Partners, Catalio Capital Management, Cormorant Asset Management, Farallon Capital Management, Fidelity Management & Research Company, Foresite Capital.
FogPharma has raised $506.0M across 4 funding rounds. Most recently, it raised $150.0M Series E in February 2024.
Key people at FogPharma.
